Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma

ConclusionsThis data suggests combination-treated cells cannot compensate for metformin-induced electron transport chain inhibition by upregulating glutaminolysis to generate TCA cycle intermediates required for cell proliferation, translating into significant reductions in tumor growth and metastatic progression. This therapeutic approach could be considered for future clinical development for OS patients presenting with or at high risk of developing metastasis.

Source: Cancer and Metabolism - March 4, 2020 Category: Cancer & Oncology Source Type: research